
|Videos|July 17, 2020
Glaucoma 360: Drug delivery contact lens technology
Author(s)Alex Delaney-Gesing
ICYMI: Chris Adams, CEO of Diopter Corp, discusses the company's drug delivery contact lens technology in the pipeline that works to treat ocular surface disease, during the 2020 Glaucoma 360 meeting in San Francisco, California.
Advertisement
ICYMI: Chris Adams, CEO of Diopter Corp, discusses the company's drug delivery contact lens technology in the pipeline that works to treat ocular surface diseases, during the 2020 Glaucoma 360 meeting in San Francisco, California.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Moorfields study reveals sharp rise in glaucoma burden across the UK
2
Why individualized glaucoma care remains essential amid uneven patient awareness
3
SpyGlass Pharma randomizes first patients in 2 phase 3 clinical trials of the BIM-IOL System
4
Study identifies corneal endothelial changes following mRNA COVID-19 vaccination
5














































